KIYATEC
Changing the future of cancer care by accurately predicting patient response to therapies before treatment begins.
Launch date
Employees
Market cap
-
Enterprise valuation
€65—98m (Dealroom.co estimates Dec 2022.)
Greenville South Carolina (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $2.2m | Convertible | |
$3.0m | Series B | ||
$2.5m | Early VC | ||
* | $18.0m | Series C | |
* | N/A | Late VC | |
| Total Funding | €26.7m | ||
Related Content
Recent News about KIYATEC
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.